Pharmacogenetics of the human drug-transporter gene MDR1: Impact of polymorphisms on pharmacotherapy

Drug Discovery Today

Volumn 6, Issue 16, 2001, Pages 835-839

  Brinkmann, Ulrich ^a   Roots, Ivar ^b   Eichelbaum, Michel ^c  

^a Epidauros Biotechnologie AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMIODARONE; ANTIARRHYTHMIC AGENT; CEFAZOLIN; CEFOTETAN; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; IVERMECTIN; MITOXANTRONE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; NICARDIPINE; NIFEDIPINE; ONDANSETRON; PHENYTOIN; PROTEINASE INHIBITOR; QUINIDINE; TACROLIMUS; TAMOXIFEN; TOPOTECAN; TRIFLUOPERAZINE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ALLELE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; DNA POLYMORPHISM; DRUG TRANSPORT; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; REVIEW;

EID: 0035882515     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01892-X     Document Type: Review

References (55)

1. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
2. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
3. A family of drug transporters: the multidrug resistance-associated proteins
4. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2
5. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
6. Multidrug resistance mediated by ATP-binding cassette transporter protein MRP
7. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells
8. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione
9. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
10. Isolation and expression of a complementary DNA that confers multidrug resistance
11. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin and vinblastine
12. p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy
13. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
14. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study
15. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
16. Clinical trials of P-glycoprotein reversal in solid tumours
17. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney
18. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells
19. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase - further experimental evidence for a multisite model
20. The multidrug resistance protein family
21. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
22. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
23. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
24. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein
25. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
26. Normal viability and altered pharmacokinetics in mice lacking MDR1-type (drug-transporting) P-glycoproteins
27. Multidrug resistance and the role of P-glycoprotein knockout mice
28. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both Mdr1a and Mdr1b genes have been disrupted
29. Contribution of the murine Mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an Mdr1a gene disruption
30. Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
31. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein
32. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
33. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice
34. Absence of the Mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A
35. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
36. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
37. The pharmacological role of P-glycoprotein in the intestinal epithelium
38. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking Mdr1a P-glycoprotein
39. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
40. The human multidrug resistance (MDR1) gene. cDNA cloning and transcription initiation
41. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface
42. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
43. Two different regions of P-glycoprotein are photoaffinity-labeled by azidopine
44. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
45. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin
46. Domain mapping of the photoaffinity drug-binding sites in p-glycoprotein encoded by mouse Mdr1b
47. Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding
48. Both P-glycoprotein nucleotide-binding sites are catalytically active
49. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines and human tumors
50. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
51. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
52. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
53. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
54. HIV-1 protease inhibitors and the MDR1 multidrug transporter
55. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?